The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 2, 1996, Pages 1103-1113

  Watts, Stephanie W ^a   Baez, Melvyn ^b   Webb, R Clinton ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCORTICOSTERONE; GUANINE NUCLEOTIDE BINDING PROTEIN; PHENOXYBENZAMINE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SODIUM CHLORIDE; 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; KETANSERIN TARTRATE; SEROTONIN 2 AGONIST; SPIPERONE;

ANIMAL; ARTICLE; DRUG EFFECT; GENETICS; HYPERTENSION; MALE; MESENTERIC ARTERY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; VASOCONSTRICTION; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; DESOXYCORTICOSTERONE; GTP-BINDING PROTEINS; HYPERTENSION; MALE; MESENTERIC ARTERIES; MOLECULAR SEQUENCE DATA; PHENOXYBENZAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SIGNAL TRANSDUCTION; SODIUM CHLORIDE; VASOCONSTRICTION;

EID: 0030302110     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. ANTONNY, B. AND CHABRE, M.: Characterization on the aluminum and beryllium fluoride species which activate transducin. Analysis of the binding and dissociation kinetics. J. Biol. Chem. 267: 6710-6718, 1992.
2. 2A receptor mRNA density and contractility in trachea and aorta from guinea pig and rat. Life Sci. 55: 105-114, 1994.
3. BALASUBRAMANIAM, G., LEE, H. S. AND MAH, S. C.: Differences in the acute and chronic antihypertensive mechanism of action of ketanserin in spontaneously hypertensive rats. J. Pharmacol. Exp. Ther. 264:129-134, 1993.
4. 2B) in rat stomach fundus longitudinal muscle. Br. J. Pharmacol. 112: 323-331, 1994.
5. BIGAY, J., DETERRE, P., PFISTER, C. AND CHABRE, M.: Fluoroaluminates activate transducin-GDP by mimicking the gamma-phosphate of GTP in its binding site. FEBS Lett. 191: 181-185, 1985.
6. BOHR, D. F., DOMINICZAK, A. F. AND WEBB, R. C.: Pathophysiology of the vasculature in hypertension. Hypertension. 18: III-69-III-75, 1991.
7. 2C receptors. Br. J. Pharmacol. 115: 622-628, 1995.
8. 1D receptors. FEBS Lett. 352: 393-399, 1994.
9. COLLIS, M. G. AND VANHOUTTE, P. A.: Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circ. Res. 41: 759-767, 1977.
10. CUMMINGS, S A., GROSZMANN, R. J. AND KAUMANN, A. J.: Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertesive rats. Br. J. Pharmacol. 89: 501-513, 1986.
11. EARL, C. Q , PROZIALECK, W. C. AND WEISS, B.: Interaction of alpha adrenergic antagonists with calmodulin Life Sci. 35: 525-534, 1984.
12. 2B receptors of endothelium-dependent relaxation in rat jugular vein. Br. J. Pharmacol. 114: 400-404, 1995.
13. FOGUET, M., HOYER, D., PARDO, L. A., PAREKH, A., KLUXEN, F. W., KALKMAN, O , STUHMER, W. AND LUBBERT, H.: Cloning and functional expression of the rat stomach fundus serotonin receptor. EMBO J. 11: 3481-3487, 1992.
14. GUO-SHU, L., DA-XIAN, H., XING-SHENG, Y., SI-RANG, W., XUE-LIN, T., JIA-LIU, X. SHU-YING, P AND YUN-ZHN, T.: Ketanserin in the treatment of hypertension: a multicentre dose-finding study in China. Clin. Exp. Hyper. A 13: 541-555, 1991.
15. 1Dβ" receptors. Eur. J. Pharmacol. 242: 75-82, 1993.
16. HERVE, P., DROUET, L., DOSQUET, C., LAUNAY, J., RAIN, B., SIMMONEAU, G., CAEN, J. AND DUROUX, P.: Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: Role of serotonin. Am. J. Med. 89: 117-120, 1990.
17. HOYER, D.: 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In The Peripheral Actions of 5-hydroxytryptamine, ed. by J. R. Fozard, pp. 73-99, Oxford University Press, Oxford, 1989.
18. HOYER, D., CLARKE, D. E., FOZARD, J. R., HARTIG, P. R., MARTIN, G. R., MYLECHARANE, W. J., SAXENA, P. R. AND HUMPHREY, P. P. A.: International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46: 158-203, 1994.
19. KALSNER, S. AND RICHARDS, R.: Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: A mechanism for coronary spasm Science 223: 1435-1437, 1984.
20. KANAGY, N. L. AND WEBB, R. C.: Enhanced vascular reactivity of mastoparan, a G protein activator, in genetically hypertensive rats. Hypertension 23: 946-950, 1994.
21. KAWASAKI, H. AND TAKASAKI, K.: Vasoconstrictor response induced by 5-hydroxy-tryptamine released from vascular adrenergic nerves by periarterial nerve stimulation. J. Pharmacol. Exp. Ther. 229: 816-822, 1984.
22. KAWASAKI, H., URABE, M. AND TAKASAKI, K.: Enhanced 5-hydroxytryptamine release from vascular adrenergic nerves in spontaneously hypertensive rats. Hypertension 10: 321-327, 1987.
23. KENAKIN, T. P.: Allotopic, noncompetitive and irreversible antagonism. In Pharmacological Analysis of Drug-Receptor Interaction, pp. 336-343, Raven Press, New York, 1993.
24. KUBO, T. AND SU, C.: Effects of serotonin and some other neurohumoral agents on adrenergic neurotransmision in spontaneously hypertensive rat vasculature. Clin. Exp. Hyper. A 5: 1501-1509, 1983.
25. 2F) from rat stomach fundus. Mol. Pharmacol. 42: 549-557, 1992.
26. 2B receptor. Mol. Pharmacol. 46: 227-234, 1994.
27. MACLENNAN, S. J., BOLOFO, M. L. AND MARTIN, G. R.: Amplifying interactions between spasmogens in vascular smooth muscle. Biochem. Soc. Trans. 21: 1145-1150, 1993.
28. MARWOOD, J. F. AND STOKES, G. S : Serotonin (5-HT) and its antagonists: involvement in the cardiovascular system. Clin. Exp. Pharmacol. Physiol 11: 439-456, 1984.
29. MCFADDEN, E. P., BAUTERS, C , LABLANCHE, J. M., LEROY, F., CLARKE, J. G , HENRY, M., SCHANDRIN, C., DAVIES, G. J., MASERI, A. AND BERTRAND, M. E.: Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina and control patients. Circulation 86: 187-195, 1992.
30. MCGREGOR, D. D. AND SMIRK, F. H.: Vascular reactivity to 5-hydroxytryptamine and hypertension in the rat. Naunyn-Schmiedeberg Arch. Pharmacol. 272: 101-116, 1970.
31. MECCA, T. E. AND WEBB, R. C.: Vascular responses to serotonin in steroid hypertensive rats. Hypertension 6: 887-892, 1984.
32. 2+ mobilization causes supersentivity of contractile response to serotonin in atherosclerotic arteries. Circ. Res. 75: 1096-1102, 1994.
33. MONSMA, F. J., SHEN, Y., WARD, R. P., HAMBLIN, M. W. AND SIBLEY, D. R.: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43: 320-327, 1993.
34. MURPHY, L., HERZOG, C., RUDICK, J., FOJO, A. AND BATES, S.: Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29: 10351-10356, 1990.
35. PLASSAT, J.-L., AMLAIKY, N. AND HEN, R.: Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol. Pharmacol 44: 229-236, 1993.
36. POMFRET, D. W., SCHENCK, K W., FLUDZINSKI, P. AND COHEN, M. L.: Interaction of 5-hydroxykynurenamine, L-kynurenine and kynuramine with multiple serotonin receptor in smooth muscle. J. Pharmacol. Exp. Ther. 241: 465-471, 1987.
37. ROTH, B. L., NAKAKI, T., CHUANG, D.-M. AND COSTA, E.: 5-hydroxytryptamine2 receptors coupled to phospholipase C in rat aorta. Modulation of phosphoinositide turnover by phorbol ester. J. Pharmacol. Exp. Ther. 238: 480-485, 1986.
38. 2B serotonin receptor. FEBS Lett. 342: 85-90, 1994.
39. 2+ efflux in arteries from DOCA hypertensive rats. Hypertension 19: 734-738, 1992.
40. THOMPSON, L., P. AND WEBB, R. C.: Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension. Hypertension 9: 277-281, 1987.
41. TURLA, M. B. AND WEBB, R. C.: Vascular responsiveness to 5-hydroxytryptamine in experimental hypertension. In The Peripheral Actions of 5-Hydroxytryptamine, ed. by J. R. Fozard, pp. 327-353, Oxford University Press, Oxford, 1989.
42. VANE, J. R.: A sensitive method for the assay of 5-hydroxytryptamine. Br. J. Pharmacol. 12: 344-349, 1957.
43. VANHOUTTE, P. M.: Serotonin, hypertension and vascular disease. Neth. J. Med. 38: 35-42, 1991.
44. VANHOUTTE, P., AMERY, A., BIRKENHAGER, W., BRECKENRIDGE, A., BUHLER, F., DISTLER, A., DORMANDY, J., DOYLE, A., FROHLICH E., HANSOOON, L., HEDNER, T., HOLLENBERG, N., JENSEN, H.-E., LUND-JOHANSEN, P., MEYER, PL., OPIE, L., ROBERTSON, I., SAFAR, M., SCHALEKAMP, M., SYMOENS, J., TRAP-JENSEN, J. AND ZANCHETTI, A.: Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin. Hypertension 11: 11-133, 1988.
45. VAN ZWIETEN, P. A., BLAUW, G. J. AND VAN BRUMMELEN, P.: Serotonergic receptors and drugs in hypertension Pharmacol. Toxicol. 70: s17-s22, 1992.
46. WAINSCOTT, D. B., COHEN, M. L., SCHENCK, K. W., AUDIA, J., NISSEN, J. S., BAEZ, M., KURSAR, J. D., LUCAITES, V. L. AND NELSON, D.: Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol. Pharmacol. 43: 419-426, 1993.
47. 2B receptor mediates vasoconstriction to 5-HT in DOCA-salt hypertensive rats. Hypertension 25: 1356, 1995.
48. WATTS, S. W. AND WEBB, R. C.: Mechanism of ergonovine-induced contraction in the mesenteric artery from deoxycorticosterone acetate-salt hypertensive rat. J. Pharmacol. Exp. Ther. 269: 617-625, 1994.
49. WINTER, J. C AND GESSNER, P. K.: Phenoxybenzamine antagonism of tryptamines, their indene isosteres and 5-hydroxytryptamine in the rat stomach fundus preparation. J. Pharmacol. Exp. Ther. 162: 286-293, 1968.